Mode
Text Size
Log in / Sign up

GnRHa treatment in familial hCG syndrome associated with concurrent beta-hCG elevation in blood and CSFWhen a Pregnancy Hormone Shows Up in a Child — and It Is Not Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note concurrent beta-hCG elevation in familial hCG syndrome may mimic malignancy.

A case report details the management of an 8-year-9-month-old girl presenting with central precocious puberty. The patient, along with her asymptomatic mother and prepubertal younger brother, received treatment with a gonadotropin-releasing hormone agonist (GnRHa). The setting was a hospital, involving a sample size of three individuals across the family unit.

During treatment, serum beta-hCG levels in the patient were elevated, ranging from 132.1 to 136.3 IU/L as measured by Roche Elecsys. Concurrently, cerebrospinal fluid beta-hCG levels were elevated at 103.22 IU/L using Abbott Architect. Elevated beta-hCG was also detected in the mother (43.79 mIU/mL) and the younger brother (64.58 mIU/mL), utilizing Abbott detection methods. Whole-exome sequencing yielded negative results for the family.

Imaging and pathological examinations identified a pineal cyst without evidence of tumor in the patient, while pathological examination noted a central neurocytoma. Oncological treatments were ceased during the course of the case. The primary outcome observed was the concurrent elevation of beta-hCG in blood and cerebrospinal fluid, which aided in the diagnosis of familial hCG syndrome and differentiation from intracranial malignancy. Evaluation of hCG variants by diverse detection antibodies was also conducted.

Safety data regarding adverse events or tolerability were not reported in the provided details. The study is a single case report, limiting the generalizability of these findings. Clinicians should recognize that elevated beta-hCG in this context may indicate familial hCG syndrome rather than a neoplastic process, particularly when family members also exhibit elevated levels.

Why This Hormone Raised Red Flags

Human chorionic gonadotropin, or hCG, is the hormone detected in pregnancy tests. In children, elevated hCG is considered a serious warning sign. It can point to germ cell tumors — a type of cancer that can grow in the brain, gonads, or elsewhere in the body.

When doctors find high hCG in a child, they act quickly. This makes sense. Germ cell tumors can grow fast, and early treatment improves survival. But the urgency of that response leaves little room for rare alternatives to be considered first.

A Case That Defied Expectations

The patient — an eight-year-old girl in China — developed early puberty signs (breast development and accelerated growth) that prompted testing. Screening revealed extremely elevated hCG in her blood. Imaging showed a small cyst in the pineal gland, a pea-sized structure deep in the brain. The picture looked worrying enough to trigger aggressive treatment.

She received chemotherapy, radiation, and eventually surgery to remove the cyst. Pathology of the removed tissue showed a central neurocytoma — a largely benign brain tumor, not the malignant germ cell tumor originally suspected. And through all of it, her hCG levels stayed persistently high. The treatments were not bringing them down.

When the Puzzle Did Not Add Up

Here is the catch: elevated hCG that does not respond to cancer treatment is a clue that something else may be going on.

Doctors eventually turned to genetic testing. They screened the girl's immediate family — and found that her mother and younger brother also had elevated hCG levels, even though neither of them had any symptoms. No tumors. No illness. Just high hCG running in the family.

This is the hallmark of familial hCG syndrome — a rare, inherited condition where the body naturally produces elevated levels of hCG due to a benign quirk in how it processes or clears the hormone. It is not cancer. It does not cause harm on its own. But its lab values look identical to those that signal danger.

How Two Different Tests Added to the Confusion

Think of hCG detection like trying to identify a specific face in a crowd — different cameras (antibody tests) may pick up slightly different features. The girl's hCG was measured using two different commercial testing platforms, Abbott Architect and Roche Elecsys, which use different antibodies to detect different forms of hCG.

Her levels were elevated on both platforms, but the exact numbers differed. This kind of variability is well-known in the field of lab medicine, but it can make it harder to know whether readings are truly alarming or whether the testing method is amplifying an artifact.

An unusual finding added to the puzzle: her hCG levels in the cerebrospinal fluid (the fluid around the brain and spine) were actually higher than in her blood — a pattern not previously described in familial hCG syndrome.

This finding significantly expands what doctors know about how this condition can present.

This was a single case report with a family-level analysis, published in Frontiers in Medicine. Researchers reviewed the girl's clinical history, imaging results, surgical pathology, lab tests across two platforms, and whole-exome sequencing (a comprehensive genetic test). First-degree relatives were also screened. A literature review of all previously documented cases of familial hCG syndrome was conducted alongside.

Whole-exome sequencing — a test that scans nearly all known genes — came back negative, meaning no specific genetic mutation was identified as the cause. This suggests the molecular basis of familial hCG syndrome may involve genetic changes not yet captured by standard testing. The girl's early puberty was ultimately attributed to a separate, unrelated condition called central precocious puberty, which was treated successfully with a hormone-regulating medication.

Once familial hCG syndrome was recognized, cancer treatment was stopped. The girl continues to be monitored, but her prognosis is considered benign.

Where This Fits in Medical Knowledge

Familial hCG syndrome is extremely rare. Only a handful of cases have been documented in the medical literature. But the consequences of missing it — or misinterpreting it as cancer — can be severe. The girl in this report received chemotherapy and radiation that, in retrospect, were not necessary for the benign cyst. Early recognition of the syndrome could have prevented that.

If your child has unexplained elevated hCG without a clear tumor on imaging, or if multiple family members show elevated hCG without symptoms, ask your doctor whether familial hCG syndrome has been considered. This is not common, but it is important to know it exists. Most children with elevated hCG do need urgent evaluation — this case does not change that. But it does show that family screening and persistent diagnostic thinking can make a critical difference.

This is a single case report, which is the lowest level of evidence in medicine. It describes one family's experience and cannot be generalized to all cases of elevated hCG. The genetic cause was not identified despite comprehensive testing, which limits the ability to screen other families efficiently.

This case adds a new data point to a very small body of literature. Researchers hope it will prompt doctors worldwide to consider familial causes when children present with persistently elevated hCG that does not respond to cancer treatment. Future research will need to identify the genetic variants responsible for familial hCG syndrome, develop clearer diagnostic criteria, and create protocols that prevent unnecessary treatment while ensuring cancer is not missed. The rare can teach medicine something important — if it is documented and shared.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
ObjectiveTo describe a rare pediatric case of familial human chorionic gonadotropin (hCG) syndrome presenting with concurrent elevation of beta-hCG (β-hCG) in both blood and cerebrospinal fluid (CSF). This report aims to expand the phenotypic spectrum of this condition and discuss diagnostic challenges to avoid misdiagnosing this benign disorder as an intracranial malignancy.MethodsClinical data were collected from the proband, an 8-year-9-month-old girl presenting with central precocious puberty (CPP) and unexplained hCG elevation. To evaluate the differential recognition of hCG variants by diverse detection antibodies, serum and CSF β-hCG levels were cross-monitored using both Abbott Architect and Roche Elecsys platforms. Additional evaluations included magnetic resonance imaging (MRI), computed tomography (CT), and pathological examination. Whole-exome sequencing (WES) and family screening of first-degree relatives were conducted to identify the etiology. A literature review regarding familial hCG syndrome was also conducted.ResultsThe patient was initially diagnosed with CPP due to breast development and accelerated growth. During routine screening to exclude tumor-associated precocious puberty, she was found to have elevated serum β-hCG (132.1–136.3 IU/L, Roche Elecsys) and was referred to our hospital. Imaging revealed a pineal cyst without evidence of tumor. Both serum and CSF β-hCG levels were elevated (45.58 and 103.22 IU/L, respectively; Abbott Architect), with CSF levels exceeding serum. Despite chemotherapy, radiotherapy, and pineal cyst resection (histology: central neurocytoma), hCG remained persistently elevated. Given the benign clinical course and lack of therapeutic response, segregation analysis was subsequently performed. Elevated serum β-hCG levels were identified in the patient’s asymptomatic mother and prepubertal younger brother (43.79 and 64.58 mIU/mL, respectively; Abbott). Whole-exome sequencing was negative. Familial hCG syndrome was finally diagnosed, and it was determined that her CPP was an independent, concurrent condition. Oncological treatments were ceased, and the girl continued gonadotropin-releasing hormone agonist (GnRHa) treatment.ConclusionThis case report describes a novel clinical finding in familial hCG syndrome characterized by concurrent elevation of β-hCG in both serum and CSF. This finding significantly expands the phenotypic spectrum of this benign condition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.